Anti-sphingosine-1-phosphate monoclonal antibodies inhibit angiogenesis and sub-retinal fibrosis in a murine model of laser-induced choroidal neovascularization

Sergio Caballero, James Swaney, Kelli Moreno, Aqeela Afzal, Jennifer Kielczewski, Glenn Stoller, Amy Cavalli, William Garland, Geneviève Hansen, Roger Sabbadini, Maria B. Grant

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

The efficacy of novel monoclonal antibodies that neutralize the pro-angiogenic mediator, sphingosine-1-phosphate (S1P), were tested using in vitro and in vivo angiogenesis models, including choroidal neovascularization (CNV) induced by laser disruption of Bruch's membrane. S1P receptor levels in human brain choroid plexus endothelial cells (CPEC), human lung microvascular endothelial cells, human retinal vascular endothelial cells, and circulating endothelial progenitor cells were examined by semi-quantitative PCR. The ability of murine or humanized anti-S1P monoclonal antibodies (mAbs) to inhibit S1P-mediated microvessel tube formation by CPEC on Matrigel was evaluated and capillary density in subcutaneous growth factor-loaded Matrigel plugs was determined following anti-S1P treatment. S1P promoted in vitro capillary tube formation in CPEC consistent with the presence of cognate S1P1-5 receptor expression by these cells and the S1P antibody induced a dose-dependent reduction in microvessel tube formation. In a murine model of laser-induced rupture of Bruch's membrane, S1P was detected in posterior cups of mice receiving laser injury, but not in uninjured controls. Intravitreous injection of anti-S1P mAbs dramatically inhibited CNV formation and sub-retinal collagen deposition in all treatment groups (p <0.05 compared to controls), thereby identifying S1P as a previously unrecognized mediator of angiogenesis and subretinal fibrosis in this model. These findings suggest that neutralizing S1P with anti-S1P mAbs may be a novel method of treating patients with exudative age-related macular degeneration by reducing angiogenesis and sub-retinal fibrosis, which are responsible for visual acuity loss in this disease.

Original languageEnglish (US)
Pages (from-to)367-377
Number of pages11
JournalExperimental Eye Research
Volume88
Issue number3
DOIs
StatePublished - Mar 2009
Externally publishedYes

Fingerprint

Choroidal Neovascularization
Lasers
Fibrosis
Monoclonal Antibodies
Endothelial Cells
Choroid Plexus
Lysosphingolipid Receptors
Bruch Membrane
Microvessels
sphingosine 1-phosphate
Retinal Vessels
Aptitude
Macular Degeneration
Visual Acuity
Rupture
Intercellular Signaling Peptides and Proteins
Collagen

Keywords

  • age-related macular degeneration
  • animal model
  • anti-angiogenesis
  • choroidal neovascularization
  • fibrosis
  • sphingosine

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Anti-sphingosine-1-phosphate monoclonal antibodies inhibit angiogenesis and sub-retinal fibrosis in a murine model of laser-induced choroidal neovascularization. / Caballero, Sergio; Swaney, James; Moreno, Kelli; Afzal, Aqeela; Kielczewski, Jennifer; Stoller, Glenn; Cavalli, Amy; Garland, William; Hansen, Geneviève; Sabbadini, Roger; Grant, Maria B.

In: Experimental Eye Research, Vol. 88, No. 3, 03.2009, p. 367-377.

Research output: Contribution to journalArticle

Caballero, S, Swaney, J, Moreno, K, Afzal, A, Kielczewski, J, Stoller, G, Cavalli, A, Garland, W, Hansen, G, Sabbadini, R & Grant, MB 2009, 'Anti-sphingosine-1-phosphate monoclonal antibodies inhibit angiogenesis and sub-retinal fibrosis in a murine model of laser-induced choroidal neovascularization', Experimental Eye Research, vol. 88, no. 3, pp. 367-377. https://doi.org/10.1016/j.exer.2008.07.012
Caballero, Sergio ; Swaney, James ; Moreno, Kelli ; Afzal, Aqeela ; Kielczewski, Jennifer ; Stoller, Glenn ; Cavalli, Amy ; Garland, William ; Hansen, Geneviève ; Sabbadini, Roger ; Grant, Maria B. / Anti-sphingosine-1-phosphate monoclonal antibodies inhibit angiogenesis and sub-retinal fibrosis in a murine model of laser-induced choroidal neovascularization. In: Experimental Eye Research. 2009 ; Vol. 88, No. 3. pp. 367-377.
@article{828f5921ccbd4374865e240b00d63b3c,
title = "Anti-sphingosine-1-phosphate monoclonal antibodies inhibit angiogenesis and sub-retinal fibrosis in a murine model of laser-induced choroidal neovascularization",
abstract = "The efficacy of novel monoclonal antibodies that neutralize the pro-angiogenic mediator, sphingosine-1-phosphate (S1P), were tested using in vitro and in vivo angiogenesis models, including choroidal neovascularization (CNV) induced by laser disruption of Bruch's membrane. S1P receptor levels in human brain choroid plexus endothelial cells (CPEC), human lung microvascular endothelial cells, human retinal vascular endothelial cells, and circulating endothelial progenitor cells were examined by semi-quantitative PCR. The ability of murine or humanized anti-S1P monoclonal antibodies (mAbs) to inhibit S1P-mediated microvessel tube formation by CPEC on Matrigel was evaluated and capillary density in subcutaneous growth factor-loaded Matrigel plugs was determined following anti-S1P treatment. S1P promoted in vitro capillary tube formation in CPEC consistent with the presence of cognate S1P1-5 receptor expression by these cells and the S1P antibody induced a dose-dependent reduction in microvessel tube formation. In a murine model of laser-induced rupture of Bruch's membrane, S1P was detected in posterior cups of mice receiving laser injury, but not in uninjured controls. Intravitreous injection of anti-S1P mAbs dramatically inhibited CNV formation and sub-retinal collagen deposition in all treatment groups (p <0.05 compared to controls), thereby identifying S1P as a previously unrecognized mediator of angiogenesis and subretinal fibrosis in this model. These findings suggest that neutralizing S1P with anti-S1P mAbs may be a novel method of treating patients with exudative age-related macular degeneration by reducing angiogenesis and sub-retinal fibrosis, which are responsible for visual acuity loss in this disease.",
keywords = "age-related macular degeneration, animal model, anti-angiogenesis, choroidal neovascularization, fibrosis, sphingosine",
author = "Sergio Caballero and James Swaney and Kelli Moreno and Aqeela Afzal and Jennifer Kielczewski and Glenn Stoller and Amy Cavalli and William Garland and Genevi{\`e}ve Hansen and Roger Sabbadini and Grant, {Maria B.}",
year = "2009",
month = "3",
doi = "10.1016/j.exer.2008.07.012",
language = "English (US)",
volume = "88",
pages = "367--377",
journal = "Experimental Eye Research",
issn = "0014-4835",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Anti-sphingosine-1-phosphate monoclonal antibodies inhibit angiogenesis and sub-retinal fibrosis in a murine model of laser-induced choroidal neovascularization

AU - Caballero, Sergio

AU - Swaney, James

AU - Moreno, Kelli

AU - Afzal, Aqeela

AU - Kielczewski, Jennifer

AU - Stoller, Glenn

AU - Cavalli, Amy

AU - Garland, William

AU - Hansen, Geneviève

AU - Sabbadini, Roger

AU - Grant, Maria B.

PY - 2009/3

Y1 - 2009/3

N2 - The efficacy of novel monoclonal antibodies that neutralize the pro-angiogenic mediator, sphingosine-1-phosphate (S1P), were tested using in vitro and in vivo angiogenesis models, including choroidal neovascularization (CNV) induced by laser disruption of Bruch's membrane. S1P receptor levels in human brain choroid plexus endothelial cells (CPEC), human lung microvascular endothelial cells, human retinal vascular endothelial cells, and circulating endothelial progenitor cells were examined by semi-quantitative PCR. The ability of murine or humanized anti-S1P monoclonal antibodies (mAbs) to inhibit S1P-mediated microvessel tube formation by CPEC on Matrigel was evaluated and capillary density in subcutaneous growth factor-loaded Matrigel plugs was determined following anti-S1P treatment. S1P promoted in vitro capillary tube formation in CPEC consistent with the presence of cognate S1P1-5 receptor expression by these cells and the S1P antibody induced a dose-dependent reduction in microvessel tube formation. In a murine model of laser-induced rupture of Bruch's membrane, S1P was detected in posterior cups of mice receiving laser injury, but not in uninjured controls. Intravitreous injection of anti-S1P mAbs dramatically inhibited CNV formation and sub-retinal collagen deposition in all treatment groups (p <0.05 compared to controls), thereby identifying S1P as a previously unrecognized mediator of angiogenesis and subretinal fibrosis in this model. These findings suggest that neutralizing S1P with anti-S1P mAbs may be a novel method of treating patients with exudative age-related macular degeneration by reducing angiogenesis and sub-retinal fibrosis, which are responsible for visual acuity loss in this disease.

AB - The efficacy of novel monoclonal antibodies that neutralize the pro-angiogenic mediator, sphingosine-1-phosphate (S1P), were tested using in vitro and in vivo angiogenesis models, including choroidal neovascularization (CNV) induced by laser disruption of Bruch's membrane. S1P receptor levels in human brain choroid plexus endothelial cells (CPEC), human lung microvascular endothelial cells, human retinal vascular endothelial cells, and circulating endothelial progenitor cells were examined by semi-quantitative PCR. The ability of murine or humanized anti-S1P monoclonal antibodies (mAbs) to inhibit S1P-mediated microvessel tube formation by CPEC on Matrigel was evaluated and capillary density in subcutaneous growth factor-loaded Matrigel plugs was determined following anti-S1P treatment. S1P promoted in vitro capillary tube formation in CPEC consistent with the presence of cognate S1P1-5 receptor expression by these cells and the S1P antibody induced a dose-dependent reduction in microvessel tube formation. In a murine model of laser-induced rupture of Bruch's membrane, S1P was detected in posterior cups of mice receiving laser injury, but not in uninjured controls. Intravitreous injection of anti-S1P mAbs dramatically inhibited CNV formation and sub-retinal collagen deposition in all treatment groups (p <0.05 compared to controls), thereby identifying S1P as a previously unrecognized mediator of angiogenesis and subretinal fibrosis in this model. These findings suggest that neutralizing S1P with anti-S1P mAbs may be a novel method of treating patients with exudative age-related macular degeneration by reducing angiogenesis and sub-retinal fibrosis, which are responsible for visual acuity loss in this disease.

KW - age-related macular degeneration

KW - animal model

KW - anti-angiogenesis

KW - choroidal neovascularization

KW - fibrosis

KW - sphingosine

UR - http://www.scopus.com/inward/record.url?scp=61549130939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61549130939&partnerID=8YFLogxK

U2 - 10.1016/j.exer.2008.07.012

DO - 10.1016/j.exer.2008.07.012

M3 - Article

C2 - 18723015

AN - SCOPUS:61549130939

VL - 88

SP - 367

EP - 377

JO - Experimental Eye Research

JF - Experimental Eye Research

SN - 0014-4835

IS - 3

ER -